If you’re a hospital CFO, 340B used to sit quietly under pharmacy operations. Not anymore.
In 2026, 340B program compliance became a finance-department priority. Between tighter HRSA audits, a possible rebate model overhaul, and a wave of new state reporting laws, the program now touches cash flow, working capital, and audit risk at the highest level.
This blog breaks down exactly where CFOs are losing revenue and compliance ground today, and gives you practical, finance-first strategies to protect both. You’ll walk away with a clear framework for maximizing 340B savings without inviting an HRSA repayment order.
Let’s get into it.
What’s Changed: The 340B Landscape CFOs Are Now Navigating
The 340B Drug Pricing Program has helped safety-net hospitals and covered entities stretch limited resources since 1992. But the program hasn’t seen a major congressional update in 15 years, even as its scope and drug purchasing volume have grown dramatically since the Affordable Care Act expanded eligibility.
That growth is exactly why regulators are circling. Here’s what’s different in 2026:
- Audit failure rates remain high. HRSA audited 115 covered entities in fiscal year 2025, and nearly 1 in 2 of those programs received adverse findings.
- A federal rebate model keeps resurfacing. HRSA’s proposed 340B Rebate Model Pilot would have shifted covered entities from upfront discounts to a rebate-based system, but a federal court vacated the pilot in February 2026 after manufacturers had already been approved to participate.
- Manufacturer data demands are expanding. Eli Lilly expanded its requirement for covered entities to submit claims-level data to include its own pharmacies, not just contract pharmacies, and other manufacturers are expected to follow.
- New federal legislation is on the table. Senate HELP Committee Chairman Bill Cassidy released a sweeping discussion draft in June 2026, the 340B Drug Pricing Integrity and Affordability for Patients Act, representing the most significant proposed overhaul of the program in over a decade.
None of this means 340B program compliance is optional or manageable through pharmacy alone. It means finance leadership needs a seat at the table.
Why 340B Compliance Has Become a CFO-Level Priority
Rising HRSA Audit Scrutiny
Audit failures aren’t random. Weak reconciliation practices and incomplete documentation are common root causes, and a hospital can fail a 340B audit simply because patient eligibility documentation is inconsistent across pharmacy and billing systems.
For CFOs, that’s a red flag. It means audit exposure often traces back to disconnected systems, not intentional wrongdoing. Standardizing documentation between pharmacy, billing, and finance is now a compliance necessity, not a nice-to-have.
The Rebate Model Threat Still Looms
Even though the rebate pilot was struck down in court, it isn’t dead. An appellate ruling referred to the planned rebate model as effectively requiring “interest-free loans” from providers to manufacturers, and provider advocates expect a revised version could launch as early as October 2026 or January 2027.
Here’s why that matters for your balance sheet:
- HRSA estimates roughly 15,250 covered entities would carry an annual burden of nearly 4 million hours under the rebate pilot.
- Health systems would need to pay full acquisition costs upfront and wait for reimbursement, straining working capital.
- Claims-level data submission requirements would create new administrative overhead and denial risk.
If your finance team hasn’t modeled a rebate scenario yet, now is the time. Waiting until the rule is finalized leaves you scrambling for cash flow contingencies under pressure.
State-Level Reporting Mandates Are Multiplying
It’s not just federal oversight. States including Minnesota, Indiana, Washington, and Virginia have introduced or expanded 340B reporting and contract pharmacy legislation in 2026, with some requiring providers to disclose total 340B revenue and how it’s spent.
CFOs operating across multiple states now need a compliance framework flexible enough to handle inconsistent, state-specific rules, not a one-size-fits-all national policy.
Where CFOs Lose 340B Revenue Without Realizing It
Most revenue leakage in 340B programs isn’t dramatic. It’s quiet, procedural, and easy to miss until an audit flags it.
Duplicate Discounts and MEF Mismatches
The Medicaid Exclusion File exists to prevent duplicate discounts, but it only works if it’s kept current. Many audit findings happen because billing practices change internally while MEF records stay outdated, creating exactly the kind of duplicate-discount exposure that triggers repayment demands.
Add to that the growing enforcement around the TB modifier for Medicaid claims. Several state Medicaid programs are tightening enforcement here in 2026, and getting it wrong can mean denied claims or compliance flags, especially for organizations operating across state lines with differing modifier rules.
Contract Pharmacy Data Gaps
As more manufacturers demand claims-level data from contract pharmacies (and now in-house pharmacies too), any gap in documentation becomes a direct revenue risk. Missing or inconsistent data can result in denied 340B pricing altogether.
Child Site Registration Confusion
A federal court overturned HRSA’s child site registration requirement in March 2026, eliminating the prior rule that off-site facilities had to be registered in the Office of Pharmacy Affairs Information System before purchasing drugs at 340B prices. That’s good news operationally, but it also means CFOs need updated internal policies to reflect the change, rather than continuing to operate under outdated registration assumptions that could create their own compliance confusion.
7 CFO Strategies for Maximizing 340B Revenue While Staying Compliant
Here’s where strategy meets execution. These are the moves finance leaders should be prioritizing right now.
- Centralize documentation across pharmacy, billing, and finance. Disconnected systems are the single biggest driver of audit failures. A shared, audit-ready data trail protects both revenue and compliance standing.
- Run a rebate-model stress test. Model what your cash flow looks like if manufacturers move from upfront discounts to post-purchase rebates. Identify your working capital gap now, not after a rule takes effect.
- Audit your MEF and TB modifier accuracy quarterly. Don’t wait for an annual review. Billing practices shift faster than records get updated, so build in a recurring check.
- Map your contract pharmacy network against manufacturer data demands. Know which relationships carry the highest documentation risk and prioritize fixing those first.
- Reassess child site registration policy. With the registration requirement vacated, update internal workflows so they reflect current rules rather than outdated compliance steps.
- Track state-specific reporting requirements by location. If you operate across multiple states, build a compliance calendar that accounts for each state’s unique 340B disclosure and modifier rules.
- Treat 340B like a revenue cycle, not a side program. As one health system CFO put it during a recent industry conference, growing manufacturer data demands mean 340B is turning into its own mini revenue cycle, complete with denials and follow-up work. Structuring it that way internally, with clear ownership and workflows, is what separates compliant, revenue-optimized programs from reactive ones.
Building a Rebate-Ready Financial Model Before You’re Forced To
Here’s the thing about regulatory uncertainty: waiting for clarity is itself a strategy, and usually the wrong one.
Even though the rebate pilot was vacated, HRSA has continued moving forward with information requests, and provider advocates expect some version of the model to return. CFOs who build a rebate scenario into their financial planning now will have a real advantage if and when it becomes mandatory.
Practical steps to start:
- Quantify your current 340B savings by drug category and manufacturer.
- Model the cash flow impact if 25 to 50 percent of your highest-volume drugs shifted to a rebate structure.
- Identify which contract pharmacy relationships would be most exposed to claims data requirements.
- Build a contingency line of credit or working capital buffer specifically earmarked for this scenario.
This isn’t about predicting exactly what Congress or HRSA will finalize. It’s about making sure 340B program compliance doesn’t become a cash flow emergency if the rules shift again.
How Strong RCM Infrastructure Supports 340B Compliance and Revenue Protection
340B compliance doesn’t live in isolation. It depends on the same underlying systems that drive your broader revenue cycle: accurate patient eligibility verification, clean claims data, consistent billing practices, and airtight documentation.
This is where many covered entities struggle, not because they lack intent to comply, but because internal RCM processes weren’t built with 340B’s specific documentation demands in mind.
That’s the gap ProMantra helps close. As a U.S.-focused revenue cycle management partner, ProMantra works with healthcare providers to strengthen the billing and documentation infrastructure that 340B compliance depends on, from eligibility verification accuracy to claims data consistency across systems. ProMantra operates under HIPAA compliance and ISO 27001 certification, giving finance and compliance teams confidence that sensitive patient and billing data is handled securely throughout the process.
For CFOs juggling audit readiness, rebate model uncertainty, and multi-state reporting mandates all at once, having a dependable RCM partner isn’t a luxury. It’s what frees up internal bandwidth to focus on strategy instead of putting out documentation fires.
FAQs
- What is the biggest 340B compliance risk for hospitals in 2026? Inconsistent documentation between pharmacy and billing systems remains the top driver of audit findings, often leading to duplicate discount issues or Medicaid Exclusion File mismatches.
- Is the 340B rebate model still happening in 2026? The original pilot was vacated by a federal court in February 2026, but HRSA has continued pursuing the concept through information requests, and industry watchers expect a revised version could return as early as late 2026 or 2027.
- How does the child site registration ruling affect covered entities? A March 2026 court ruling eliminated the requirement for off-site facilities to be registered in HRSA’s system before purchasing 340B-priced drugs, giving covered entities more flexibility, but internal policies should be updated to reflect this change.
- Why are manufacturers demanding more claims data from covered entities? Manufacturers are expanding data submission requirements, initially for contract pharmacies and now increasingly for in-house pharmacies too, to verify eligible patient dispensing and avoid duplicate discounts.
- How can CFOs prepare for potential 340B reforms without waiting for final rules? By modeling cash flow scenarios under a rebate structure, auditing MEF and modifier accuracy regularly, and centralizing documentation across finance, billing, and pharmacy teams now.
Ready to Strengthen Your 340B Compliance Foundation?
340B program compliance in 2026 is no longer just a pharmacy responsibility. It’s a finance-level priority that touches cash flow, audit risk, and long-term revenue stability.
If your team is looking to shore up the billing and documentation infrastructure that supports 340B compliance, ProMantra can help you build a more resilient, audit-ready revenue cycle.
Contact ProMantra today to discuss how our RCM expertise can support your compliance and revenue goals.
